| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5521165 | Drug Discovery Today | 2017 | 5 Pages |
Abstract
Rheumatoid arthritis, a systemic autoimmune disease, causes chronic joint inflammation and bone destruction. Interleukin (IL)-20's association with this disease, and its expression and regulation has been extensively studied since 2006. Anti-IL-20 antibody has paved the way to clinical trials aimed at blocking the pathogenic actions of IL-20 in rheumatoid arthritis. This review focuses on current knowledge of IL-20's involvement in the pathogenesis of rheumatoid arthritis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Yu-Hsiang Hsu, Ming-Shi Chang,